Abstract
Care for older adults with cancer is complex as they often present with multiple comorbidities and polypharmacy, have poor performance status and limited social supports. These factors often lead to exclusion from standard therapy and clinical trials. In the past decade, treatment of NSCLC has changed due to novel therapeutics with improved tolerability due to lower adverse effect profile, leading to increased uptake of systemic therapy. The study goal is to compare the uptake of systemic therapy in adults with advanced NSCLC before and after the availability of targeted therapy and immunotherapy, and to examine the evolution in treatment patterns between younger and older adults.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
